Results 201 to 210 of about 286,453 (328)

Mitochondrial DNA Variation, Antiretroviral Therapy, and Incidence of Diabetes Among Men With and Without HIV. [PDF]

Open Forum Infect Dis
Cronin C, Brown TT, Hsu HY, Samuels DC, Tong W, Sarkar S, Abraham AG, Martinson JJ, Hussain SK, Wolinsky S, Hulgan T, Sun J.   +11 more
europepmc   +1 more source

Parametric modelling of survival following HIV and AIDS in the era of highly active antiretroviral therapy: data from Australia

, 2011
Fatemeh Nakhaee, Matthew Law
openalex   +1 more source

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim, Ingrid F. Metzger, Jessica Bo Li Lu, Todd C. Skaar, Zeruesenay Desta   +4 more
wiley   +1 more source

Reduced Adherence to Antiretroviral Therapy in Pregnant Women With HIV With Intimate Partner Violence in the United States. [PDF]

Open Forum Infect Dis
Villavicencio A, Jemmott JB, Ghadimi F, Nkwihoreze H, Seyedroudbari S, Short WR, Rana A, Sheth AN, Scott RK, Lazenby GB, Wright RL, Momplaisir FM.   +11 more
europepmc   +1 more source

Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts [PDF]

Thierry Tiendrebeogo, Karen Malateste, Armel Poda, Albert Minga, Eugène Messou, Henri Chenal, Oliver Ezechi, Didier Koumavi Ekouévi, Igho Ofotokun, Marcel Zannou, Armel Poda, Oliver Ezechi, Eugène Messou, Henri Chenal, Kla Albert Minga, Aristophane Tanon, Moussa Seydi, Ephrem Mensah, Caroline Yonaba, Lehila Bagnan Tossa, Jocelyn Dame, Sylvie Marie N’Gbeche, Kouakou Kouadio, Madeleine Amorissani Folquet, François Tanoh Eboua, F Traoré, Agatha David, Elom Takassi, Antoine Jaquet, Didier Koumavi Ekouévi, François Dabis, Renaud Becquet, Charlotte Bernard, Karen Malateste, Olivier Marcy, Marie Kerbie Plaisy, Elodie Rabourdin, Thierry Tiendrebeogo, Désiré Lucien Dahourou, Sophie Desmonde, Julie Jesson, Valériane Leroy, Raoul Moh, Jean-Claude Azani, Jean Jacques Koffi, Eric Komena, Maika Bengali, Abdoulaye Cissé, Guy Gnepa, Apollinaire Horo, Simon Boni, Eulalie Kangah, Corinne Moh, Jeanne Eliam, Ighovwerha Ofotokun, Chris Martin, Noelle A. Benzekri, Geoffrey Goettlieb, Olivia Keiser, Antoine Jaquet, Didier Koumavi Ekouévi, Ighovwerha Ofotokun, Renaud Becquet, Noelle A. Benzekri, Charlotte Bernard, Simon Boni, François Dabis, Désiré Lucien Dahourou, Sophie Desmonde, Didier Koumavi Ekouévi, Antoine Jaquet, Julie Jesson, Eric Komena, Valériane Leroy, Karen Malateste, Ighovwerha Ofotokun, Marie K. Plaisy, Elodie Rabourdin, Thierry Tiendrebeogo, Thierry Tiendrebeogo   +79 more
openalex   +1 more source

Risk Factors for Acute Liver Enzyme Abnormalities in HIV-Hepatitis B Virus-Coinfected Patients on Antiretroviral Therapy [PDF]

, 2007
O Chauvel, Karine Lacombe, Philippe Bonnard, Caroline Lascoux‐Combe, Jean‐Michel Molina, Patrick Miailhes, Pierre‐Marie Girard, Fabrice Carrat   +7 more
openalex   +1 more source

Determinants of viral load non-suppression among people living with HIV on antiretroviral therapy in Kumasi, Ghana

, 2021
David Ansah, Emmanuel Kumah, Vitalis Bawontuo, Peter Agyei‐Baffour, Emmanuel Kwasi Afriyie   +4 more
openalex   +2 more sources

Enhanced Clearance of HIV‐1 Broadly Neutralizing Antibody VRC07‐523‐LS During Viremia: Influences on Trial Design and Analysis

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Broadly neutralizing antibodies (BNAb) are capable of neutralizing multiple HIV‐1 strains through the targeting of conserved epitopes. This study's objective was to quantify the pharmacokinetic (PK) parameters describing the distribution and elimination of the BNAb VRC07‐523‐LS in people with HIV (PWH), and to identify the influence of viral ...
Nicholas M. Smith, Brian M. Ho, Katharine J. Bar, Lucio Gama, Gabrielle Dziubla, Richard A. Koup, Michael Pensiero, Leonid Serebryannyy, Marina Caskey, Timothy J. Wilkin, Troy D. Wood, Gene D. Morse, Charles S. Venuto, Ray Cha, Qing Ma   +14 more
wiley   +1 more source

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

HIV Medicine, Volume 27, Issue 2, Page 217-225, February 2026.
Abstract Objective Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). Methods This is a retrospective cohort study at a single‐centre primary care HIV clinic.
Tali Faggiano, Jeffrey Yin, Nimish Patel, Afsana Karim, Kari Abulhosn, Laura Bamford, Lucas Hill   +6 more
wiley   +1 more source

Longitudinal T-Cell Phenotypic Dynamics During Sustained Antiretroviral Therapy in People With HIV. [PDF]

Open Forum Infect Dis
Vanpouille C, Wells A, DeGruttola V, Lynch M, Zhang X, Tu XM, Chaillon A, Woodworth B, Gaitan N, Rawlings SA, Landay A, Weber KM, Scully EP, Karn J, Gianella S.   +14 more
europepmc   +1 more source